New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis–Related Kidney Disease
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
&NA; Epidemiologic data show an association between the prevalence and severity of nonalcoholic fatty liver disease and the incidence and stage of chronic kidney disease (CKD); furthermore, nonalcoholic steatohepatitis (NASH)‐related cirrhosis has a higher risk of renal failure, a greater necessity for simultaneous liver‐kidney transplantation, and a poorer renal outcome than cirrhosis of other etiologies even after simultaneous liver‐kidney transplantation. These data suggest that NASH and CKD share common proinflammatory and profibrotic mechanisms of progression, which are targeted incompletely by current treatments. We reviewed therapeutic approaches to late preclinical/early clinical stage of development in NASH and/or CKD, focusing on anti‐inflammatory and antifibrotic treatments, which could slow the progression of both disease conditions. Renin inhibitors and angiotensin‐converting enzyme‐2 activators are new renin‐angiotensin axis modulators that showed incremental advantages over angiotensin‐converting enzyme inhibitors/angiotensin‐receptor blockers in preclinical models. Novel, potent, and selective agonists of peroxisome proliferator‐activated receptors and of farnesoid X receptor, designed to overcome limitations of older compounds, showed promising results in clinical trials. Epigenetics, heat stress response, and common effectors of redox regulation also were subjected to intensive research, and the gut was targeted by several approaches, including synbiotics, antilipopolysaccharide antibodies, Toll‐like receptor‐4 antagonists, incretin mimetics, and fibroblast growth factor 19 analogs. Promising anti‐inflammatory therapies include inhibitors of NOD‐like receptor family, pyrin domain containing 3 inflammasome, of nuclear factor‐&kgr;B, and of vascular adhesion protein‐1, chemokine antagonists, and solithromycin, and approaches targeting common profibrogenic pathways operating in the liver and the kidney include galectin‐3 antagonists, and inhibitors of rho‐associated protein kinase and of epidermal growth factor activation. The evidence, merits, and limitations of each approach for the treatment of NASH and CKD are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237 · cited 1×
“Obeticholic acid (OCA; INT-747), a potent semisynthetic derivative of chenodeoxycholic acid, reversed renal lipid accumulation, proteinuria, and tubulointerstitial inflammation and fibrosis in diet-induced experimental CKD(43,44) and improved NAFLD histologic activity and fibrosis score in the multicenter, randomized…”
BackgroundKang, H. M., Ahn, S. H., Choi, P., Ko, Y.-A., Han, S. H., Chinga, F., Park, A. S. D., Tao, J., Sharma, K., Pullman, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3762 · Cited by 1,555 · cited 1×
“intermediates, leading to lipoperoxidative stress, cell apoptosis, inflammation, and fibrosis.(23,24) In NASH and CKD, ectopic lipid accumulation is subtended by an extensive derangement in multiple steps in triglyceride and cholesterol metabolism, including defective catabolism and increased synthesis and uptake from…”
BackgroundMicroRNAs 103 and 107 regulate insulin sensitivity
Trajkovski, M., Hausser, J., Soutschek, J., Bhat, B., Akin, A., Zavolan, M., Heim, M. H., & Stoffel, M. (2011) · Nature · doi:10.1038/nature10112 · Cited by 1,000
Nox4 Is a Protective Reactive Oxygen Species Generating Vascular NADPH Oxidase
Schröder, K., Zhang, M., Benkhoff, S., Mieth, A., Pliquett, R., Kosowski, J., Kruse, C., Luedike, P., Michaelis, U. R., Weissmann, N., et al. (2012) · Circulation Research · doi:10.1161/circresaha.112.267054 · Cited by 622 · cited 1×
“Although the results are encouraging to date, potential safety issues deriving from inhibition of normal physiological function of NOX remain: NOX4 protects the vasculature from ischemic or inflammatory damage by enhancing endothelial nitric oxide synthase and heme oxygenase-1 expression and nitric oxide production.(6…”
BackgroundTomlinson, E., Fu, L., John, L., Hultgren, B., Huang, X., Renz, M., Stephan, J. P., Tsai, S. P., Powell-Braxton, L., French, D., et al. (2002) · Endocrinology · doi:10.1210/endo.143.5.8850 · Cited by 576
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456
Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414
Palmer, S. C., Mavridis, D., Navarese, E., Craig, J. C., Tonelli, M., Salanti, G., Wiebe, N., Ruospo, M., Wheeler, D. C., & Strippoli, G. F. M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62459-4 · Cited by 395 · cited 1×
“Although the renin-angiotensin system (RAS) contributes to the pathogenesis of obesity-related disorders, including NAFLD and CKD, a considerable proportion of CKD patients on angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) develop end-stage renal disease or cardiovascular disea…”
BackgroundJha, J. C., Gray, S. P., Barit, D., Okabe, J., El-Osta, A., Namikoshi, T., Thallas-Bonke, V., Wingler, K., Szyndralewiez, C., Heitz, F., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013070810 · Cited by 352
Lefebvre, E., Moyle, G., Reshef, R., Richman, L. P., Thompson, M., Hong, F., Chou, H.-L., Hashiguchi, T., Plato, C., Poulin, D., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158156 · Cited by 323
Cited by
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis
Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9607 · Cited by 449
“Possible differences can be explained by the differential effects of pioglitazone and rosiglitazone on inflammation and fibrosis mechanisms, such as through up-regulation of adiponectin, activationof adenosinemonophosphate–activatedproteinkinase, and induction of hepatic stellate cell senescence.(25,26) Thebenefitsofp…”
BackgroundSelf-citationNAFLD as a driver of chronic kidney disease
Byrne, C. D., & Targher, G. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.01.013 · Cited by 449
Mantovani, A., Zaza, G., Byrne, C. D., Lonardo, A., Zoppini, G., Bonora, E., & Targher, G. (2018) · Metabolism · doi:10.1016/j.metabol.2017.11.003 · Cited by 348
Musso, G., Pinach, S., Mariano, F., Saba, F., De Michieli, F., Framarin, L., Berrutti, M., Paschetta, E., Parente, R., Lizet Castillo, Y., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000000937 · Cited by 31
Self-citation
Metadata
- Authors
- Musso, G., De Michieli, F., Bongiovanni, D., Parente, R., Framarin, L., Leone, N., Berrutti, M., Gambino, R., Cassader, M., Cohney, S., & Paschetta, E.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 15
- Issue
- 7
- Pages
- 972-985
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2511572965
- Cited by
- 38
- References
- 16
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis–Related Kidney Disease. https://app.cochat.ai/papers/10.1016/j.cgh.2016.08.002
- The paper
- Musso, G., De Michieli, F., Bongiovanni, D., Parente, R., Framarin, L., Leone, N., Berrutti, M., Gambino, R., Cassader, M., Cohney, S., & Paschetta, E. (2017). New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis–Related Kidney Disease. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2016.08.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.